{"calculatePct":false,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"37"},{"groupId":"OG001","value":"38"}],"units":"Participants"}],"description":"SAEs were defined as any untoward medical occurrence that at any dose resulted in death, was life threatening, requires inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity or was a congenital anomaly/birth defect. A pulmonary infection SAE was a serious event in the MedDRA system organ class \"infections and infestations\" and a preferred term of bronchitis, influenza, pneumonia, pneumonia bacterial, respiratory tract infection, upper respiratory tract infection or viral upper respiratory tract infection.","groups":[{"description":"Participants received placebo IV once daily on Days 1 to 3 of each 21-day E/P chemotherapy cycle.","id":"OG000","title":"Part 2: Placebo"},{"description":"Participants received trilaciclib 240 mg/m\\^2 IV once daily on Days 1 to 3 of each 21- day E/P chemotherapy cycle.","id":"OG001","title":"Part 2: Trilaciclib 240 mg/m^2"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"The FAS included all randomized patients who received at least 1 dose of study drug (etoposide, carboplatin, or trilaciclib). Analyses using the FAS were conducted on the basis of the assigned treatment.","reportingStatus":"POSTED","timeFrame":"From randomization to the end of the treatment period (a minimum of 51 days up to a maximum of 379 days)","title":"Occurrence of Pulmonary Infection SAE in Part 2","type":"SECONDARY","unitOfMeasure":"Participants"}